Myoblast transplantation for cardiac repair: a clinical perspective.
The incidence of heart failure is achieving epidemic proportions. Adult human myocytes cannot regenerate because these cells do not re-enter the cell cycle. In patients with heart failure, myoblast transplantation is emerging as a potential therapeutic option to augment the function of remaining myocytes. Both skeletal myoblasts and autologous bone marrow cell transplantation, after intensive preclinical experimental animal studies, have entered phase I safety studies in humans. Most of these clinical trials have involved small groups of patients and cell transplantation was carried out as an adjunct to coronary revascularization. Preliminary results show that the procedure is safe and leads to improved myocardial function. This paper reviews and summarizes the outcome of these phase I trials involving skeletal myoblast transplantation.
Haider
Husnain Kh
HKh
National University Medical Institutes, National University of Singapore, 119074.
Tan
Alvin C K
AC
Aziz
Salim
S
Chachques
Juan C
JC
Sim
Eugene K W
EK
D000818:Animals; D001208:Asia / Q000453:epidemiology; D002303:Cardiac Output, Low / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D017690:Cell Transplantation / Q000009:adverse effects / Q000401:mortality; D017321:Clinical Trials, Phase I as Topic; D005060:Europe / Q000453:epidemiology; D006801:Humans; D032448:Myoblasts, Skeletal / Q000502:physiology / Q000637:transplantation*; D014182:Transplantation, Autologous; D014481:United States / Q000453:epidemiology